ICCC — IMMUCELL CORP /DE/

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 811641 ·
Last close
$10.50
Market Cap
$94.99M
52W High
$10.74
52W Low
$6.00
ADV30
31,734
Next earnings
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 10,357,295 4,657,444 1,969,316 1,941,607 44,108,374 6,812,637 14,973,334
Dec 2025 7,625,999 2,910,209 -57,956 -2,849,142 42,532,447 3,806,831 15,476,967
Sep 2025 5,506,122 2,363,098 20,075 -139,748 45,730,123 3,886,198 15,929,282
Jun 2025 6,444,880 2,817,924 569,562 501,880 46,720,898 5,998,494 16,853,470

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,475,292
Investing CF
$-1,214,307
Financing CF
$-1,212,386
CapEx
$-1,250,439
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.11
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-15,203,753
Inventory
$9,267,369
Receivables
$3,450,186
ST Investments
EBIT TTM
$-578,614
Pretax Income TTM
$-1,028,457
Interest Exp TTM
$449,843
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$29,934,296
EBITDA
$5,882,925
Free Cash Flow
$3,078,906
Enterprise Value
$97,518,352
Total Cash
$6,812,637
Total Debt
$12,777,384
Shares Out
9,046,799
Trailing EPS
$-0.07
Book Value
$2.99
ROE
-1.9%
ROA
4.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 27,644,174 1,649,305 -1,040,027 42,532,447 15,476,967 2,475,292
Dec 2024 26,493,169 -1,640,159 -2,156,629 45,100,477 17,582,290 357,903
Dec 2023 17,471,669 -5,748,078 -5,774,598 43,808,102 18,815,025 -4,674,236
Dec 2022 18,567,962 -2,298,943 -2,493,805 44,860,649 14,480,600 -1,543,871

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.11

Peers — same industry

TickerNameMarket CapLastDaily %
MXCT MAXCYTE, INC. $107.12M $1.00
ONMD OneMedNet Corp $48.17M $0.88
IMDX Insight Molecular Diagnostics Inc. $207.95M $6.44
TKNO Alpha Teknova, Inc. $213.92M $3.99
QCLS Q/C TECHNOLOGIES, INC. $30.94M $3.94

News headlines (Yahoo Finance, 1h cache)

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
2026-05-25 13:45 · Yahoo
ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
2026-05-15 23:01 · Yahoo
ImmuCell Q1 Earnings Call Highlights
2026-05-15 15:06 · Yahoo
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
2026-05-14 20:05 · Yahoo
Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity
2026-05-13 08:18 · Yahoo
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
2026-05-07 20:05 · Yahoo
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
2026-04-22 07:59 · Yahoo
Top Stock Reports for Goldman Sachs, NextEra Energy & Shopify
2026-04-21 20:17 · Yahoo
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
2026-04-13 20:38 · Yahoo
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
2026-04-08 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.